Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Luminex; Life Technologies; CombiMatrix; Danaher; Biotrial, Warnex; Almac

NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the firm to repurchase up to the lesser of $22.5 million worth or 900,000 shares of the company's outstanding common stock. The repurchase program is scheduled to expire Dec. 31, 2013, Luminex noted in a regulatory filing with the US Securities and Exchange Commission. As of Feb. 21, Luminex had nearly 41.7 million common shares outstanding, according to its Form 10-K filed on Friday.


Life Technologies said this week that the new Center for Personalized Medicine at the Roswell Park Cancer Institute has purchased four Ion Proton and two Ion Personal Genome Machine sequencers. Roswell Park announced the launch of the new center earlier this month and said it had already spent $16 million to fund equipment and infrastructure.


CombiMatrix said in a filing with the SEC this week that it has issued an aggregate of 120,029 shares of common stock to an accredited investor upon such investor's successive conversions of an aggregate of $240,000 of the stated value of the firm's Series A 6 percent Convertible Preferred. It also issued an aggregate of 8,480 shares of common stock to the investor as make-whole dividend payments in satisfaction of the aggregate amount of $25,485 in make-whole dividend payments under the Certificate of Designation of Preferences, Rights and Limitations of Series A 6 percent Convertible Preferred Stock of the company. In addition, CombiMatrix issued an aggregate of 565 shares of common stock to the investor as dividends accrued from Jan. 1, 2013 through the date of conversion on the converted Series A Stock due under the Certificate of Designation.

As a result of these issuances, CombiMatrix said that it has issued more than 5 percent of its outstanding shares of common stock in unregistered transactions since the last report that it filed under Item 3.02 with the Securities and Exchange Commission. The company now has 2,275,567 shares of common stock issued and outstanding.


Danaher said this week that its board of directors has approved a quarterly dividend of $.025 per share payable on April 26 to shareholders of record on March 28.


Biotrial has completed the acquisition of the Warnex Bioanalytical Services division. Warnex inked the C$6 million (US$6 million) deal in October, paving the way for it to wind down its active operations.


Almac announced this week that its Sciences Business Unit had successfully completed a US Food and Drug Administration inspection of its analytical facilities in Craigavon, Northern Ireland. It said that the inspection, which included its test labs and specialist analytical facilities, passed the inspection with no objectionable conditions or recommendations for improvement.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.